Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination with BYL719, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma
A study for patients with uveal melanoma using study drug AEB071
Sponsor: Novartis Pharmaceuticals Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN4901
U.S. Govt. ID: NCT02273219
Contact: Richard Carvajal MD: 212-305-2055 / rdc2150@cumc.columbia.edu
Additional Study Information: The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that dose. Study visits will also consist of blood work, MRI's, questionnaires and ECGs.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you had any major surgery or extensive radiotherapy within the last month? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal MD
rdc2150@cumc.columbia.edu
212-305-2055
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE